Lilly's next-generation 'triple-G' drug beat Ozempic on weight and blood sugar in a late-stage trial

In an 80-week late-stage trial, Lilly's once-weekly drug retatrutide — nicknamed 'triple-G' because it activates three hormone receptors at once, combining appetite suppression, blood-sugar control and increased calorie burning — outperformed the highest approved dose of Ozempic on both headline measures. Blood sugar, measured by A1C, fell by an average of 2.2% on retatrutide versus 1.8% on Ozempic. People on retatrutide lost an average of 44.3 pounds on the 9 mg dose and 47.4 pounds on the 12 mg dose, compared with 20.9 pounds on Ozempic, and saw greater improvements in several cardiovascular risk factors. 'Based on these results, we believe retatrutide, if approved, could shift the treatment paradigm for people living with type 2 diabetes, obesity and related conditions,' said Kenneth Custer, president of Lilly Cardiometabolic Health. The drug is not yet approved — but the direction of travel for millions of patients is clear.

SDG 3 · Good health and well-being — Mechanism: tech innovation